title: Anti-atherogenic properties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy.
abstract: Some of the medications used for the management of schizophrenia are associated with clinically significant increases in weight and adverse alterations in serum lipid levels. The aim of the study was to investigate the effect of short-term (two months) treatment with atypical anti-psychotics on coronary heart disease risk factors, including the functional properties of high-density lipoprotein (HDL), in psychiatric patients. Nineteen patients diagnosed with schizophrenia, schizoaffective, and bipolar disorder and ten healthy volunteers were enrolled in the study. In the present study blood was drawn at baseline and after two months of atypical anti-psychotic treatment. Wilcoxon non-parametric-test was used to examine differences in the psychotic group before and two months after treatment.Waist circumference and oxidative stress in psychiatric patients were higher compared with the control group. Serum-mediated cholesterol efflux capacity was lower in psychotic patients compared to controls. Two months of anti-psychotic therapy was associated with increased abdominal obesity, decreased paraoxonase lactonase activity, but with no further change in serum-mediated cholesterol efflux from macrophages. Psychotic patients have low serum-mediated cholesterol efflux from macrophages as a parameter of HDL functionality. Atypical anti-psychotic treatment for two months increased metabolic derangements in these patients but without further decrement in serum-mediated cholesterol efflux.
authors.affiliation: Internal Medicine Department A, Ziv Medical Center, Safed, Israel Faculty of Medicine, Bar-Ilan University, Safed, Israel Osama.h@ziv.health.gov.il.
authors.forename: Osamah
authors.initials: O
authors.lastname: Hussein
authors.affiliation: Department of Psychiatry, Ziv Medical Center, Safed, Israel Faculty of Medicine, Bar-Ilan University, Safed, Israel.
authors.forename: Lidia
authors.initials: L
authors.lastname: Izikson
authors.affiliation: Internal Medicine Department A, Ziv Medical Center, Safed, Israel.
authors.forename: Yunis
authors.initials: Y
authors.lastname: Bathish
authors.affiliation: Internal Medicine Department A, Ziv Medical Center, Safed, Israel.
authors.forename: Enas
authors.initials: E
authors.lastname: Dabur
authors.affiliation: Internal Medicine Department A, Ziv Medical Center, Safed, Israel.
authors.forename: Alaa
authors.initials: A
authors.lastname: Hanna
authors.affiliation: Department of Oncology, Ziv Medical Center, Safed, Israel Faculty of Medicine, Bar-Ilan University, Safed, Israel.
authors.forename: Jamal
authors.initials: J
authors.lastname: Zidan
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D043303:Aryldialkylphosphatase / Q000378:metabolism; D050197:Atherosclerosis / Q000139:chemically induced* / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D008075:Lipoproteins, HDL; D043303:Aryldialkylphosphatase
keywords: Psychotic patients; atypical anti-psychotic medications; high-density lipoprotein functionality